Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Improving CardioCheck PA analytical performance: three-year study
Insights
Point-of-care testing (POCT) for lipid disorders requires ongoing quality management. Continuous surveillance improved the CardioChek PA device, making it suitable for cardiovascular screening programs.
Area of Science:
- Clinical Chemistry
- Point-of-Care Testing
- Cardiovascular Disease Prevention
Background:
- Dyslipidemia is a major cardiovascular risk factor, often undiagnosed and undertreated.
- Point-of-care testing (POCT) enables rapid clinical decisions but requires quality assessment.
- The CardioChek PA (CCPA) portable lipid analyser has limited performance evidence.
Purpose of the Study:
- To assess the analytical performance of the CardioChek PA (CCPA) device.
- To identify and address performance issues for improved diagnostic accuracy.
Main Methods:
- A 3-year evaluation of CCPA accuracy, precision, and inter-instrument/lot variability.
- Comparison with a standard laboratory method for lipid analysis.
Main Results:
- Initial CCPA evaluation showed underestimation of total cholesterol (6.5% bias) and high CVs (>6%).
- Manufacturer-driven system improvements led to certified performance by 2013 (e.g., 1.3% total error for total cholesterol).
Conclusions:
- Continuous quality management is crucial for POCT diagnostic tests.
- External quality surveillance over 3 years significantly improved CCPA performance.
- The enhanced CCPA device is now adequate for lipid disorder screening programs.
Background:
Cardiovascular prevention requires a diagnostic approach for population-based screening programmes aimed at early identification of modifiable risk factors. Dyslipidaemia, which is a major risk factor for cardiovascular disease, remains largely undiagnosed and undertreated. Point-of-care testing (POCT) provides immediate results for clinical decision-making, however, quality assessment is essential to ensure system performance requirements. CardioChek PA (CCPA), a portable whole blood analyser for rapid lipid measurement, has been on the market since 2002 but with limited evidence of performance levels. The aim of the study was to assess analytical performance issues of the device and possibly contribute to their solution.
Methods:
Over a 3-year period, we repeatedly evaluated CCPA accuracy, precision, and discrepancies between instruments and between test strip lots by comparison with laboratory method. At our initial evaluation, the CCPA analyser underestimated total cholesterol (bias 6.5%) and gave within-assay CVs above 6% for all lipid fractions. Our results solicited sequential improvements to the CCPA system by the manufacturer up to the performance level certified by the Cholesterol Reference Method Laboratory Network in 2013: total error 1.3% for total cholesterol and 3.1% for high density lipoprotein (HDL) cholesterol.
Conclusions:
POCT diagnostic tests need continuous quality management, including both quality control and quality assurance, to monitor the analytical process. A 3-year external quality surveillance provided information useful in improving POCT performance. As a result, the device is now adequate for use in screening programmes aimed at early detection of lipid disorders.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:17Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:29Pathophysiology of Cardiac Performance